| abstract |
The present invention relates generally to a new cluster of molecules that affects oxidative stress, inflammation, and/or insulin signaling in white blood cells, particularly monocytes, and to identifying the optimal method or system to modulate the activity of said molecules. Thereby reducing the risk of diseases associated with activated monocytes such as obesity and obesity-related metabolic syndrome disorder phenotype characterized by dyslipidemia, hypertension, glucose intolerance, insulin resistance and diabetes, lipid homeostasis disorders and/or cardiovascular diseases. More in particular these molecules are microRNAs (miRNAs or miRs) that can be present in the cell, in cell-derived vesicles that are secreted in blood, and can be detected in plasma or serum. In addition, we present a method, for instance a diagnostics method or system, for instance a diagnostic, which provides information on how to modulate the molecules to treat or prevent obesity, to separate responders from non-responders, and to treat or prevent the obesity-related metabolic syndrome disorders. |